era-net pathogenomics m. karrasch, fzj 23.05.2005

ERA-NET PathoGenoMics

M. Karrasch, FZJ23.05.2005

www.pathogenomics-era.net



1. What is an ERA-NET?

2. Structure of the ERA-NET PathoGenoMics / Boards, Work programme and activities

3. Transnational Research Activities

4. The today‘s subject: Strategic Research Agenda



ERA-NET: new instrument within the FP 6 Objective: “Strengthening the European Research Area“ (ERA)

ERA-NET Schema

Objective:

development and implementation of joint research activities

enhance the cooperation and coordination of national research activities

- through networking of national/regional programmes including their mutual opening and the



ERA-NET Scheme

Eligible Partners:

Partners are programme owners/managers acting on behalf of national/regional public authorities :

such as ministries, funding agencies, research councils

ERA-NET does not include direct research funding, but

all measures for intergovernmental coordination of existing

or new funding programmes.



Network Steering CommitteeNSC

Funding Organisations

Affiliated PartnersFunding Organisations

External Advisory BoardEAB

Scientists

Boards

Executing Board EBProgramme/Project Management

CoordinatorJoint SecretariatAdministration

EuropeanCommission



ERA-NET Schema

Activities:

1. Systematic exchange of information & “best practices”

2. Common strategies

3. Development of common activities

4. Implementation of transnational research activities



WP 7Development of a legal, contractual and financial Framework and application/ evaluation system

01/2006

WP 3development of a „European Research Agenda“

WP 1 + 2

information exchange about the national programmes

Commitment of the partners regarding joint call

WP 8first

Joint call

2005 2006

Agreement on „European Research Agenda“

9/2005

Agreement Framework and application/ evaluation system

Development of transnationalresearch consortia

WP 6Partne-ring Event

4/2005

WP 4 SMEs/industry working group, PIPs network (PathoGenoMics innovation partners)

WP 6 Working group on training issues

WP 9 Science and Society: IT-based communication platforms for the public, Printed information material, On-spot-presentations



Work programmemilestones

deliverables

WP 7 development of the admin. framework + Application/ evaluation system

WP 6 working group „training issues“

WP 4 SMEs/industry working group

WP 9 Wissenschaft und Gesellschaft: Kommunikationsplattform

WP 6 development of transnationalresearch concortia

WP 3 development of a „strategic Research Agenda“

Austria, Finland,France, Germany,Slovenia, Spain

maybe: Portugal, Sweden

12/2005

WP 1 + 2

information exchange about the national programmes

Commitment of the partners regarding joint call

2005 2006

Agreement about SRA

9/2005

Agreement about admin. framework and appl./ eval. system

4/2005

2007

WP 81st

jointcall WP 8

Project execution

WP 82ndjointcall

Partne-ring Event

Call text and IPR guideline:1st draft 04/05

2nd and 3rd draft 05/05final version 08/05

2004

10/2004Start

Strategic Research Agenda:1st draft 06/05

final version 09/05



Public accessible database, contains information about and allows searches for:

- Research groups in the Pathogenomics field- topics of current research projects- Studied microorganisms

Will probably be available in 4 weeks-> please supplement these information with e.g.

summaries of your own research topics, link to your web page…

WP 9 Science and Society: IT-based communication platforms for the public, Printed information material, On-spot-presentations



Transnational Research Activities:

- „nationality principle“ (each country shall fund ist own research entities)

- countries participating in the first joint call:

maybe also participating:

- research groups from other countries may also participate, provided they have their own funding

Austria, Finland, Germany, Slovenia, Spain

France, Israel, Latvia, Portugal, Sweden



Transnational Research Activities:

- who may submit proposals?Research groups, organised in transnational consortia, will submit a consorted proposal

- which topics will be funded?Topics covering Genome Research on pathogenic

Microorganisms (details will be given in the call for proposals, approx. Jan. 2006)

- will there be further regulations?yes, e.g. transnational research consortia, consorted proposalsvariable geometrie; details are still to be definedfurther regulations will be published in the call text






4. The today‘s subject: Strategic Research Agenda for PathoGenoMics



Agreement on SRA

Helsinki26.-27.09.05

Expert Meeting: indepth discussion about SRA, develop-ment of a first draft SRA by Rapporteurs

2005

Paris23.-25.05.05 06/2005

Publication of the SRA draft in FEMS letters (and other journals)

07/2005

Scientific feedback

Time schedule: Strategic Research Agenda (SRA)



Workpackage 3: Strategic Research Agenda (SRA)

Why a Strategic Research Agenda for PathoGenoMics?

To define the most important topics for future PathoGenoMics researchTo outline the importance of this topic

-> basis for discussions with

- national funding authorities (e.g. development of new programmes)- European Commission- other stakeholders



Pathogenomics: A Proposed European Research Agenda

A: The microbes

B: Host-microbe interactions

C: Development and improvement of tools

D. Integration at a European Level



T 3.2 Indepth discussion with high-level experts, 23rd – 25th May 2005, Paris

Based on first ideas to structure a European Research Agendadeveloped on a 1st preparatory meeting (June 2003, Würzburg)

3.2(a) Civil Aspects of pathogenomics3.2(b) Impact of pathogenomics on biosecurity and safety research




T 3.3 Feedback from the scientific community

“Rapporteurs“ will summarise the indepths expert discussion and continue drafting the agenda (up to 20 pages)

Draft Research Agenda will be published in FEMS Letters in order to create a scientific „feedback loop“ (deadline approx. 2 months)

final version of the „European Pathogenomics Research Agenda“in September 2005




Partner Country Participation in the first call to be published in January 2006

Participation in the second call to be published in January 2007

Austria (bm:bwk) Yes Yes

Finland Yes Yes

France maybe maybe

Germany Yes Yes

Hungary

Israel maybe maybe

Latvia maybe maybe

Portugal maybe maybe

Slovenia Yes Yes

Spain Yes Yes

Affiliated Partners

Austria (FWF) No No

Lithuania Yes Yes

Malta Yes Yes

Netherlands No No

Norway

Sweden maybe maybe

UK (BBSRC) No No

UK (WT)



Partner Country

External Advisory BoardName Institute/ Company

1 + 2, Germany

Prof. Dr. Matthias Frosch Institut für Hygiene und Mikrobiologie, University of Wuerzburg

Prof. Dr. Klaus-Peter Koller Aventis Deutschland GmbH, Frankfurt

3, Austria Prof. Dr. Heinz Redl LBI für exp. und klin. Traumatologie, Unfallkrankenh. L. Böhler, Wien

Prof. Dr. Michael Wagner Abt. Mikrobielle Ökologie, Institut für Ökologie, Universität Wien

4, Finland Prof. Timo Korhonen University of Helsinki

Prof. Mikael Skurnik University of Helsinki

5, France Prof. Dr. Michele Mock Institute Pasteur, Paris

Prof. Dr. Christophe d'Enfert Unité Biologie et Pathogenicite Fongiques, Institute Pasteur, Paris

Prof. Dr. Andrée Lazdunski IBSM / CNRS Marseille

6, Hungary Prof. Dr. Béla Nagy Vet. Med. Research Inst. of the Hung. Academy of Sciences, Budapest

Prof. Dr. Levente Emody University of Pécs, Faculty of Medicine

7, Israel Prof. Dr. Eliora Z. Ron Faculty of Life Sciences, Tel-Aviv University

8, Latvia Prof. Pauls Pumpens University of Latvia, Biological Faculty

Prof. Vaija Zilevica University of Latvia, Medical Faculty

9, Portugal

10, Slovenia

Prof. Dr. Peter Raspor Chair for Biotechnology, Biotechnical Faculty, University of Ljubljana

Asst.prof. Dr. Roman Jerala Laboratory of Biotechnology, National Institute of Chemistry, Ljubljana

11, Spain Prof. Dr. Francisco García-del Portillo

Centro Nacional de Biotechnología, Campus de Cantoblanco, Madrid

Prof. Dr. Carlos Martin University of Zaragoza

era-net pathogenomics m. karrasch, fzj 23.05.2005

Documents